BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the therapy in a broad population for which the...
BC Extra | Aug 22, 2019
Financial News

Microbiome company Finch raises $53M ahead of anti-infective readout

Finch's series C round is designed to carry the microbiome company through what could be a pivotal data readout next year in Clostridium difficile infection, while also allowing it to continue building on a pair...
BC Innovations | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
BC Week In Review | Mar 2, 2018
Financial News

Finch Therapeutics raises $36 million series B round

Finch Therapeutics Group Inc. (Somerville, Mass.) raised $36 million on March 1 in an oversubscribed series B round from Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital. The original target was $30 million....
BC Extra | Mar 1, 2018
Financial News

Finch Therapeutics raises $36M series B round

Finch Therapeutics Group Inc. (Somerville, Mass.) raised $36 million in an oversubscribed series B round from Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital. The original target was $30 million. CEO Mark Smith...
BC Week In Review | Oct 27, 2017
Company News

Microbiome companies Finch and Crestovo merge

Microbiome companies Crestovo LLC (Cambridge, Mass.) and Finch Therapeutics Inc. (Somerville, Mass.) merged to form Finch Therapeutics Group (Somerville, Mass.), which will focus on developing oral alternatives to fecal microbiota transplant. Crestovo's lead candidate, CP101...
BC Extra | Oct 23, 2017
Company News

Microbiome companies Finch and Crestovo merge

Microbiome companies Crestovo LLC (Cambridge, Mass.) and Finch Therapeutics Inc. (Somerville, Mass.) merged to form Finch Therapeutics Group (Somerville, Mass.), which will focus on developing oral alternatives to fecal microbiota transplant. Crestovo's lead candidate, CP101...
BC Week In Review | Jul 21, 2017
Clinical News

Crestovo starts Phase II trial of CP101 to treat CDI

Crestovo LLC (Cambridge, Mass.) began the Phase II PRISM 3 trial evaluating CP101 to prevent recurrent Clostridium difficile infection. The double-blind, placebo-controlled, U.S. trial is evaluating two doses of CP101 in about 240 patients. The...
Items per page:
1 - 8 of 8